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Abstract
Background: Accumulation of hyperphosphorylated tau is a major neuropathological feature of tauopathies
including Alzheimer’s disease (AD). Serum amyloid A (SAA), an acute-phase protein with cytokine-like property, has
been implicated in amyloid deposition. It remains unclear whether SAA affects tau hyperphosphorylation.
Methods: Potential involvement of SAA in tau hyperphosphorylation was examined using intracerebral injection of
SAA, and in Saa3−/− mice receiving systemic administration of lipopolysaccharide (LPS). Induced SAA expression
and microglial activation were evaluated in these mice using real-time PCR and/or immunofluorescence staining.
Cultured primary neuronal cells were treated with condition media (CM) from SAA-stimulated primary microglial
cells. The alteration in tau hyperphosphorylation was determined using Western blotting.
Results: Saa3 is the predominant form of SAA proteins induced by LPS in the mouse brain that co-localizes with
neurons. Overexpression of SAA by intracerebral injection attenuated tau hyperphosphorylation in the brain.
Conversely, Saa3 deficiency enhanced tau phosphorylation induced by systemic LPS administration. Intracerebral
injection of SAA also induced the activation of microglia in the brains. IL-10 released to CM from SAA-stimulated
microglia attenuated tau hyperphosphorylation in cultured primary neurons. IL-10 neutralizing antibody reversed
the effect of SAA in the attenuation of tau phosphorylation.
Conclusions: LPS-induced expression of SAA proteins in the brain leads to the activation of microglia and release
of IL-10, which in turn suppresses tau hyperphosphorylation in a mouse model of systemic inflammation.
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Background
Accumulating evidence suggests that neuroinflammation
is a common pathological feature of tauopathy, charac-
terized with intracellular accumulation of tau proteins in
neurodegenerative disorders such as Alzheimer’s disease
(AD) [1]. Microglia, the resident macrophages in the
brain, are the primary immune cells responsible for the
detection of invading pathogens and neuronal injuries in
the central nervous system (CNS) [2]. Activated micro-
glia are observed in the postmortem brain tissues of
various human tauopathies including Alzheimer’s disease
[3]. Microglial cells can be activated not only by injury
and infection [4] but also by stimulators including amyl-
oid beta (Aβ) [5] and serum amyloid A (SAA) [6].
Activated microglial cells in turn exhibit dramatic mor-
phological changes, proliferate, migrate, and produce a
variety of pro- and anti-inflammatory mediators [4, 7]
such as interleukin-1 (IL-1), IL-6, and IL-18, which
accelerate tauopathy including the formation of neuro-
fibrillary tangles (NFTs) [8–11]. Although these findings
suggest a possible link between neuroinflammation and
tauopathy, there is little evidence for direct regulation of
activated microglia in the pathological accumulation of
the microtubule-associated protein tau.
Human SAA is a family of proteins consisting of
SAA1, SAA2, and SAA4 [12]. Among these proteins,
SAA1 and SAA2 are the major acute-phase proteins
primarily synthesized by hepatocytes during acute-phase
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response [13]. However, extrahepatic production of SAA
has been implicated as being more relevant to the patho-
genesis of chronic inflammatory diseases including AD
[13]. In mice, SAA is encoded by a family of three indu-
cible genes, Saa1, Saa2, and Saa3, plus a constitutively
expressed Saa4. The major site of their synthesis is the
liver; however, Saa3 is also expressed in extrahepatic
tissues in response to lipopolysaccharide (LPS) stimula-
tion [14]. SAA has cytokine-like properties that modu-
late several cellular responses. SAA induces monocytes
and neutrophils migration and stimulates the production
of cytokines, chemokines, and matrix metalloproteinases
(MMPs) [15–20]. Although the inducible SAA proteins
are barely detectable in normal brains, SAA has been
found in the brains of patients with AD [13, 21]. More-
over, SAA has been found to colocalize with Aβ deposits
in AD brains [22], and the induction of a systemic acute-
phase response in SAA transgenic mice enhances amyloid
deposition [23]. Despite these findings, a correlation be-
tween SAA and tauopathy has not been established.
In this study, we found that the expression of the
mouse SAA protein, Saa3, in the mouse brain was mark-
edly increased in a LPS injection model of systemic
inflammation. We evaluated the effects of SAA on tau
phosphorylation in Saa3 gene knockout (Saa3−/−) mice
with systemic LPS injection and in mice receiving intra-
cerebral injection of SAA. The results have shown that
the SAA proteins significantly attenuate tau hyperpho-
sphorylation in these mouse models. Moreover, SAA has
been found to regulate the activation of microglia in
these mouse models. Finally, we have observed that IL-
10 released from SAA-stimulated microglia attenuates
tau hyperphosphorylation in neurons. Based on these
findings, we postulate that SAA plays a role in tauopathy
in part through the regulation of microglia activation.
Methods
Reagents
Primary antibodies used in this study are listed in
Additional file 1: Table S1. The BCA protein assay kit
and 4,6-diamidino-2-phenylindole (DAPI) were obtained
from Beyotime Institute of Biotechnology (Nantong,
Jiangsu, China). Mouse and rabbit control IgGs were
purchased from Santa Cruz Biotechnology (Dallas, TX).
IRDye®800CW secondary antibodies were from LI-COR
(Lincoln, NE). Dulbecco’s modified Eagle’s medium
(DMEM), neurobasal-A, and B-27® supplements were
purchased from Life Technologies (Carlsbad, CA). Other
chemicals were obtained from Sigma Chemical Company
(St. Louis, MO).
Animals
The Saa3−/− (Saa3 knockout) mice in C57BL/6 genetic
background were obtained from the Knockout Mouse
Project (KOMP) Repository (Davis, CA). Age- and sex-
matched littermates were used in the experiments. The
C57BL/6 mice were purchased from SLACCAS Labora-
tory Animal Co., Ltd (Shanghai, China). The generation
of the Saa3 transgenic mice is described in Additional
file 2. All mice were housed (four to five animals per
cage) with a 12/12 h light/dark cycle, with ad libitum
access to food and water. The housing, breeding, and
animal experiments were in accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals, with procedures approved by the
Biological Research Ethics Committee of Shanghai Jiao
Tong University.
LPS administration
Lipopolysaccharide (LPS, from Salmonella enterica
serotype Abortus equi, Sigma-Aldrich, Cat. No. L5886,
Lot 032M4067) at a low concentration (5 mg/kg body
weight) or a high concentration (15 mg/kg body weight)
was intraperitoneally injected into 3-month-old C57BL/6
mice consisting of Saa3−/− and their respective wild-type
(WT) littermates (n = 4 per group; half males and half
females). The mice received either LPS or an equal
volume of normal saline. After 24 h, all mice were sacri-
ficed by decapitation and their brains removed immedi-
ately. The hippocampi and cerebral cortices of the left
hemisphere of the mouse brain were dissected, flash
frozen in dry ice, and stored at −80 °C for biochemical
analyses later. The right hemispheres of the mouse
brains were fixed with 4 % paraformaldehyde in 0.1 M
phosphate-buffered saline (PBS), followed by cryoprotec-
tion in 30 % sucrose. Coronal sections of 30-μm thick-
ness were cut using a freezing sliding microtome. The
sections were stored in glycol anti-freeze solution (ethylene
glycol, glycerol, and 0.1 M PBS in 3:3:4 ratio) at −20 °C until
immunohistochemical staining.
Stereotaxic intracranial injection of SAA
Three-month-old C57BL/6 mice were randomly divided
into control (saline) and SAA (recombinant human apo-
SAA; Pepro Tech, Rocky Hill, NJ) (n = 4 in each group;
half males and half females). Mice were anesthetized by
intraperitoneal injection of 50 mg/kg pentobarbital
sodium (Sigma) and then restrained onto a stereotaxic
apparatus (RWD Life Science, Shenzhen, China). For
stereotaxic intracranial injection of SAA, an earlier
method was used [24]. After surgically exposed, the
duramater and drilled holes in the skull, SAA (20 μg/
8 μl) dissolved in saline was bilaterally injected into the
left and right hippocampi (two sites, 4 μl per site), using
a 10-μl Hamilton syringe with a 26-gauge needle. The
injection rate was 0.5 μl/min, and the needle was kept
in each site for an additional 3 min before a gentle
withdrawal. The bregma coordinates were determined
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as follows: anterior, −2.0 mm; lateral, ±1.3 mm; verti-
cal, −2.2 mm. As controls, the mice stereotaxically
received equal volume of normal saline. Postopera-
tively, all mice were placed on heating pads (37 °C)
until recovered from surgery. After 48 h, the injected
mice were sacrificed by decapitation and the brain
samples were prepared as with the LPS-treated mice
described above.
For brain injection of SAA with IL-10 neutralizing
antibody (BD Pharmingen, San Diego, CA), SAA
(10 μg per site, two sites) with IL-10 neutralizing
antibody (4 μg per site, two sites) were stereotaxic-
ally injected into the left and right hippocampi of
the 3-month-old C57BL/6 mice (n = 4 in each group;
half males and half females). As controls, the mice
received an equal volume of SAA dissolved in saline
(20 μg/8 μl) or normal saline alone (8 μl). After
48 h, the injected mice were sacrificed by decapita-
tion and the brain samples were prepared as with
the LPS-treated mice described above.
Total RNA extraction and real-time PCR
Total RNA was extracted from the cortex and hippo-
campus of the mouse brain and primary cultures of
neurons, astrocytes, and microglial cells using TRIzol
reagent (Invitrogen). One microgram of the RNA was
used for reverse transcription using the Reverse Tran-
scription System A3500 kit (Promega, Madison, WI).
The complementary DNA (cDNA) was subsequently
subjected to Real-Time PCR to quantify the transcripts
of TNF-α, IL-6, IL-10, Saa1, and Saa2, and Saa3 using
SYBR® Green Real-time PCR Master Mix (TOYOBO,
Osaka, Japan). The following primers were used: TNF-α
(5′-TTC TCA TTC CTG CTT GTG G-3′; 5′-ACT
TGG TGG TTT GCT ACG-3′), IL-6 (5′-CTT CTT
GGG ACT GAT G-3′; 5′-CTG GCT TTG TCT TTC
T-3′), IL-10 (5′-AGG GTT ACT TGG GTT GC-3′; 5′-
TGA GGG TCT TCA GCT TC-3′), Saa1 (5′-TTG
TTC ACG AGG CTT TC-3′; 5′-TTT GTC AGG CAG
TCC AG-3′), Saa2 (5′-TGA TGC TGC CCA AAG G-
3′; 5′-GCC AGG AGG TCT GTA GTA A-3′), and
Saa3 (5′-CCT TCC ATT GCC ATC A-3′; 5′-GGG
TCT TTG CCA CTC C-3′). The primers for the mouse
housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) were 5′-CCT TCC GTG TTC CTA
CC-3′ and 5′-CAA CCT GGT CCT CAG TGT A-3′.
PCR was performed according to the following condi-
tions: 94 °C for 3 min, 40 cycles of denaturation at
94 °C for 30 s, annealing at 56 °C for 45 s, and ex-
tension at 72 °C for 30 s, followed by a final exten-
sion at 72 °C for 10 min. The quantitative fold
changes in messenger RNA (mRNA) in each sample
were normalized to GAPDH expression and calculated
using the 2exp(−ΔΔCt) method.
Western blot analysis
Mouse brain tissues and cultured neuronal cells were ho-
mogenized in lysis buffer containing 50 mM Tris-HCl (pH
7.4), 8.5 % sucrose, 1.0 mM EGTA, 1.0 mM EDTA, 1.0 %
sodium dodecylsulfate, 10 mM β-mercaptoethanol, prote-
ase, and phosphatase inhibitor cocktails (Sigma-Aldrich).
Protein concentrations were determined using a BCA Pro-
tein Assay Kit (Beyotime Biotechnology, Nantong, China)
and then heated in 5×SDS-PAGE loading buffer (Beyotime
Biotechnology) at 99 °C for 7 min. Tissue and neuronal
cell homogenates were separated on 10 or 12 % SDS-
PAGE and transferred onto nitrocellulose membranes
(Whatman Protran, Dassel, Germany). Blots were blocked
with 5 % non-fat milk for 1 h at room temperature and
incubated overnight at 4 °C with primary antibodies in-
cluding Tau5 (1:2000); the anti-phospho-tau antibodies
pS199 (1:2000), pS205 (1:2000), pS396 (1:2000), pS404
(1:2000), anti-Saa3(1:500), and anti-β-actin (1:10000),
followed by the respective IRDye®800CW secondary
antibodies (LI-COR Biosciences, Lincoln, NE). The
membranes were scanned using the 800-nm channel of
an Odyssey® CLX Infrared Imaging System. The immu-
noreactive bands were quantified using the NIH Image
J software.
Immunofluorescence staining
Sections of mouse brain were washed with 0.05 M Tris-
buffered saline (TBS) (containing 0.05 M Tris buffer
and 9 g/L NaCl, pH 7.4) for 15 min and then perme-
abilized with 0.1 % Triton X-100 in TBS for 15 min and
blocked with 5 % normal goat serum (NGS) for 30 min
at room temperature. The sections were incubated
overnight at 4 °C with anti-Iba1 (1:500) in TBS with
5 % NGS. After washing with TBS for 15 min, the
sections were incubated with Alex Fluor®568 donkey
anti-rabbit antibody (1:500, Invitrogen) at room
temperature for 1 h. Again, after three washes in TBS,
the sections were stained for nuclei with 5 μg/ml of
DAPI for 10 min at room temperature and mounted on
glass slides. To identify the expression of Saa3 in
neuron, microglia, or astrocyte, the brain sections were
first stained with anti-MAP-2 (1:200), anti-CD11b
(1:200), or anti-glial fibrillary acidic protein (GFAP)-
Cy3TM (1:500) antibody overnight and incubated in
Alex Fluor®633 donkey anti-mouse or Alex Fluor®555-
donkey anti-rat IgG (1:500; Invitrogen) for 1 h. The
sections were rinsed in TBS, stained with anti-Saa3
antibody (1:200) overnight at 4 °C, and incubated with
an Alex Fluor®488 donkey anti-rabbit antibody (1:500;
Invitrogen) for 1 h. Sections were counterstained with
DAPI for 10 min, and then fluorescent confocal images
were captured using a laser-scanning confocal fluores-
cence microscope (TCS SP8, Leica Microsystems,
Wetzlar, Germany).
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Images for the quantification of fluorescence intensity
of Saa3, CD11b and GFAP were acquired at ×400
magnification. The relative immunofluorescence inten-
sity of Saa3, CD11b, and GFAP was quantified using the
ImageProPlus Software (Media Cybernetics, Silver
Spring, MD). The results were expressed as mean ± SEM
based on a minimum of three sections per animal and
three 8-bit RGB digital images at the CA1 per animal (n = 4
mice per group).
To exclude obscure influence of Saa3 on microglial
proliferation, the number of Iba1-positive cells was
taken into consideration. Integrated optical density of
red fluorescence (Iba1 positive area capture) was nor-
malized against the integrated optical density of blue
fluorescence (the DAPI positive area captured), using
the Image ProPlus 6.0 software and expressed as
mean ± SEM per group (three sections per animal,
with images acquired at ×200 magnification; three 8-bit
RGB digital images at the dentate gyrus (DG) and CA3
region per animal; n = 4).
Primary neuronal cultures
Neuronal cultures were prepared in cortices from
newborn (postnatal day 0) WT mouse pups as described
before [25]. In brief, cerebral cortices were removed
from the brains of mice, the meanings and microvessels
were removed, and tissues were minced with a sterile
razor blade. Tissues were digested with 0.025 % trypsin
(Sigma) and 0.01 % DNase I (Sigma) at 37 °C for 10 min.
The cell suspension was filtered through a 200-mesh
sieve, and cells were plated on poly-D-lysine (Sigma)-
coated 24-well plates at a density of 5 × 105 cells per
well. Two hours later, the DMEM medium was replaced
with neurobasal medium containing 2 % B-27® supple-
ments for 2 days. Culture medium were changed to
neurobasal with 10 % fetal bovine serum (FBS) and
3 μg/ml cytosine-β-D-arabinofuranoside (Ara-C, Sigma)
in the following 3 days and then again switched back to
neurobasal medium containing 2 % B-27® supplements.
Experiments were performed on days 7–8 after initiation
of the culture.
Primary microglial and astrocyte cultures
Microglial and astrocyte cultures were prepared from
newborn (postnatal day 0) WT mouse pups as described
before [6, 25, 26]. Specifically, separated cells were cul-
tured in poly-D-lysine coated 75 cm2 flasks with DMEM
medium (containing 10 % FBS, 100 U/ml penicillin, and
100 g/ml streptomycin sulfate). The medium was replen-
ished on day 1 and day 3. On day 7, microglia cells in
the culture flasks were shaken off at 260 rpm for 2.5 h,
and the remaining astrocytes were maintained in DMEM
with 10 % FBS. Experiments were performed after two
passages of the cells.
SAA and LPS treatment in vitro
Primary neuronal cells, astrocyte cells, and microglial
cells were stimulated with LPS at indicated concentra-
tions or with PBS for 24 h. Total RNA was extracted for
real-time PCR to detect cell-specific expression of Saa3.
For the analysis of the effect of SAA on neuronal tau
phosphorylation, primary neuronal cells were treated
with the recombinant human SAA (PeproTech, Rocky
Hill, NJ; 0.5 μΜ for 3, 6 and 12 h), and the neuronal
lysates were prepared for Western blot analysis as
mentioned above.
Preparation of conditioned media from microglia and
astrocytes
The microglia cells and astrocyte were plated at a dens-
ity of 1 × 106 cells per well onto a 12-well plate for
experiments involving the collection of conditioned
media. The cells were treated with 0.5 μΜ SAA or PBS
(control) for 6 h. The medium was removed and
replaced with fresh DMEM. The cells were incubated
for another 12 h, and the conditioned medium (CM)
was collected. Half of the medium in the primary
neurons was replaced with equal volume of CM from
SAA-stimulated or PBS (control) cell culture. After 3, 6,
and 12 h of incubation, neuronal lysate was prepared
and blotted for Western analysis. To determine the
effect of IL-10, an IL-10-neutralizing antibody (25 μg/
ml; BD Pharmingen, San Diego, CA) was added to CM
30 min before application to primary cultures of
neurons. After 12 h of incubation, neuronal lysate was
prepared and Western blot analysis was conducted.
ELISA
The IL-10 in the microglial conditioned medium was
measured using enzyme-linked immunosorbent assay
(ELISA) kit (eBioscience, San Diego, CA), according to
the instructions of the vender. Briefly, the conditioned
medium and mouse IL-10 standard samples were incu-
bated in the IL-10 ELISA plates at 4 °C overnight. After
washed plates three times with PBST (PBS + 0.5 %
Tween-20) and blocked with 3 % BSA in PBS for 1 h at
37 °C, biotin-conjugate anti-mouse IL-10 antibody was
incubated in the wells at 37 °C for 90 min. The plate
was emptied and washed three times with PBST.
Substrate solution was pipetted into each well after dry-
ing and incubated in 37 °C for 10 min. The enzymatic
reaction was stopped by adding stop solution per well.
The concentration of IL-10 was determined by measur-
ing absorbance at 450 and 630 nm. All the experiments
were done in three separate experiments.
Statistical analysis
Data are presented as mean ± SEM from at least three ex-
periments. One-way ANOVA followed by Newman-Keuls
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test or student’s t test was performed using the statistic
software GraphPad Prism 5 (San Diego, CA). p values less
than 0.05 was considered statistically significant.
Results
Systemic LPS administration enhances neuroinflammation
and Saa3 expression in mouse brain
To evaluate the function of SAA in tau phosphorylation,
SAA expression and distribution in the mouse brain was
examined using a systemic inflammation model [27, 28].
Three-month-old C57BL/6 mice were given a single
dose of LPS at 5 and 15 mg/kg through intraperitoneal
injection. The control mice received an equal volume of
normal saline. After 24 h, brain extracts from hippocam-
pus and cortex were collected (Fig. 1a). Systemic admin-
istration of LPS induced neuroinflammation in the
brain, as evidenced by a modest but significant increase
in the transcripts of the pro-inflammatory cytokines IL-6
and TNF-α in the hippocampus and cortex (Fig. 1b).
The effect of systemic LPS administration in SAA ex-
pression in the brain was next examined. All three indu-
cible mouse Saa transcripts were elevated in the
hippocampus and cortex (Fig. 1c). Of note, there was a
3500-fold increase in the hippocampus and a 600-fold
increase in the cortex of the Saa3 transcript in mice re-
ceiving 15 mg/kg of LPS compared to mice receiving
normal saline (Fig. 1c). These results suggest that, in the
mouse brain, Saa3 is the predominant form of SAA in-
duced by LPS. The inducible expression of Saa3 was
confirmed at the protein level using a specific antibody
against Saa3, as shown in Western blots with two ran-
domly chosen brain samples from mice receiving 15 mg/
kg of LPS compared to those receiving normal saline
(Fig. 1d).
In addition to immunoblotting, immunofluorescence
staining was performed to confirm the increase in Saa3
expression and its distribution in the mouse brain. Stain-
ing of serial slices from WT mouse brain with an anti-
Saa3 antibody and Alexa Fluor 488-conjugated second-
ary antibody identified a significant up-regulation of
Saa3 (green fluorescence) in the CA1 (Fig. 2a–c) and
DG (Additional file 3: Figure S1) regions of the hippo-
campus as well as in the cortex (Additional file 3: Figure
S2) of mice receiving LPS, compared with mice receiving
saline. To identify the cellular origin of Saa3, double im-
munostaining was performed for Saa3 and the cell-
specific markers MAP2 (neurons), CD11b (microglia),
and GFAP (astrocytes). The Saa3 protein was colocalized
with MAP2 (Fig. 2a, Additional file 3: Figures S1A and
S2A) and, to a lesser extent, with GFAP in the DG area
of the hippocampus (Additional file 3: Figure S1C) and
in the cortex (Additional file 3: Figure S2C). No Saa3
protein colocalization was visible in CD11b-positive
cells, although induced expression of CD11b was evident
in microglia from the LPS-injected mice (Fig. 2b,
Additional file 3: Figures S1 and S2). These results show
a much higher level of inducible Saa3 expression in neu-
rons than in astrocytes, but not in microglia. Since Saa3
is reported to stimulate glial cells [6], its role in the acti-
vation of microglia and astrocytes after LPS injection
was next examined. The expression of GFAP, a protein
abundant in activated astrocytes, did not change in mice
receiving LPS (Fig. 2c, d). In contrast, the CD11b-
immunoreactive cells displayed a hypertrophic morph-
ology, a sign of microglial activation. The expression of
CD11b in these cells was significantly higher than that
in the control (saline) samples (Fig. 2c, d). Altogether,
these results demonstrate that Saa3 is the major form of
SAA proteins induced by LPS in mouse neurons and
astrocytes.
SAA deficiency potentiates tau phosphorylation in LPS-
injected mice
To determine whether the elevated Saa3 expression
plays a role in neuroinflammation and AD development,
Saa3 gene knockout (Saa3−/−) mice were generated
(Fig. 3a). The success of Saa3 deletion was functionally
confirmed in mice receiving systemic LPS administra-
tion, which led to elevated Saa3 expression in WT but
not the Saa3−/− mice (Fig. 3b, c). These mice were next
compared for the extent of tau hyperphosphorylation, a
major pathological feature of AD [1]. The contents of
total tau (detected by the Tau5 antibody), non-
phosphorylated tau (detected by the Tau1 antibody), and
phosphorylated tau at two AD-related amino acid posi-
tions (detected by antibodies against pT205 and pS396,
respectively) were determined in the hippocampus of
Saa3−/−mice and their WT littermates that received LPS
or saline. As shown in Fig. 3d, e, there was an increase
in tau phosphorylation at T205 and S396 in WT and
Saa3−/− mice receiving LPS injection, compared to mice
receiving saline injection. A decrease in the level of non-
phosphorylated tau in LPS-injected mice was also evi-
dent when normalized against total tau (Tau5). When
the Saa3−/− mice were compared with their WT litter-
mates, the Saa3−/− mice showed an additional increase
in tau phosphorylation at T205 and S396, along with a
more evident decrease in non-phosphorylated tau be-
tween the saline-injected mice and LPS-injected mice
(Fig. 3d, e). The results were further confirmed by im-
munofluorescence staining analysis. As expected, after
systemic LPS treatment, the expression of phosphory-
lated tau at T205 had an additional increase in neuronal
cells from the Saa3−/− mouse (Additional file 3: Figure
S3), but not in astrocytes (Additional file 3: Figure S4).
These findings suggest a role for Saa3 in restraining tau
hyperphosphorylation induced by systemic LPS
administration.
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Transgenic expression of Saa3 attenuates tau
hyperphosphorylation
To further evaluate the potential involvement of Saa3 in
regulating tau hyperphosphorylation, transgenic mice ex-
pressing Saa3 were generated. Based on our finding that
induced Saa3 expression was seen mainly in neurons, the
Saa3 transgenic (Saa3-Tg) mice were prepared using the
neuron-specific synapsinI (SYNI) promoter (Additional
file 3: Figure S5A–B; see Additional file 2 for detail).
Transgenic expression of Saa3 increased the basal and
inducible Saa3 mRNA level (Additional file 3: Figure
S5C). Of note, the basal and inducible expression of Saa3
was also enhanced at the protein level in the Saa3-Tg mice
(Additional file 3: Figure S5D–E). To determine whether
Saa3 was secreted by neurons, primary neuronal cultures













































































































Fig. 1 Induced expression of SAA and selected inflammatory cytokines in the mouse brain after systemic administration of LPS. a A schematic
representation of experimental design. Three-month-old C57BL/6 mice were injected i.p. with LPS at either 5 mg/kg body weight (L-LPS) or
15 mg/kg body weight (H-LPS) or with same amount of saline (control). Twenty-four hours later, the mice were sacrificed and the hippocampus
and cerebral cortex were collected for analysis. b Real-time PCR quantification of the transcripts for IL-6 and TNF-α in the tissue samples of the
hippocampus (left) and cortex (right) 24 h after LPS or saline (control) administration. The relative transcript expression was calculated as 2-ΔΔCT
and was normalized against saline controls. c relative mRNA levels of Saa1, Saa2, and Saa3 in extracts of hippocampus (left) and cortex (right)
determined using the same procedure as in b. For each group, four mice were used and the data shown are the means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.0001. d Two representative Western blots showing the 12-kDa Saa3 protein in the hippocampus (left) and cortex (right), following
LPS (15 mg/kg body weight) stimulation for 24 h. An anti-Saa3 antibody was used for blotting
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Fig. 2 Immunofluorescence staining of Saa3 in the CA region of the hippocampus. Frozen sections from the left hemisphere of mice were
stained for Saa3 protein using a rabbit anti-Saa3 antibody and Alexa Fluor 488-conjugated anti-rabbit IgG (green fluorescence). The sections were
subsequently stained for neurons (anti-MAP2; a), microglia (anti-CD11b; b), or astrocytes (anti-GFAP; c), all in red fluorescence (see the “Methods”
section for detail). Cell nuclei were stained with DAPI (blue fluorescence). Immunofluorescence was detected using a confocal laser-scanning
microscopy. Images shown are representative of multiple experiments (n = 4 for each group; scale bar, 50 μm). Arrowheads in the merged image
mark the positions of the double-stained cells. d quantification of the tissue expression level of Saa3, CD11b, and GFAP after LPS stimulation
(15 mg/kg, 24 h). The results are expressed as the means ± SEM from at least three mice per group, each in duplicates or triplicates. *p < 0.05
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WT littermates were stimulated with 0.1 or 1 μg/ml of
LPS for 24 h. The ELISA result showed a higher level of
Saa3 protein in the culture medium from Saa3-Tg mice
than non-Tg mice, either with or without LPS stimulation
(Additional file 3: Figure S5F). These results validate the
transgenic expression of Saa3 in the mouse brain.
To investigate whether transgenic expression of Saa3
affects tau phosphorylation, the level of total tau and
phosphorylated tau at T205 and S396 was determined in
Saa3-Tg mice and non-Tg controls following systemic LPS
administration (Additional file 3: Figure S6). When normal-
ized against total tau, an increase in tau phosphorylation at
T205 and S396 was observed in non-Tg mice injected with
LPS compared with that of saline controls. In the Saa3-Tg
mice, however, the level of LPS-induced tau phosphoryl-
ation at T205 and S396 was lower than that of the non-Tg
mice.
Intracerebral injection of SAA attenuates tau
hyperphosphorylation
Intracerebral injection has been used widely to assess
the effects of drugs and cell-derived factors in brain
functions. To further evaluate the potential involvement
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Fig. 3 Genetic deletion of Saa3 promotes LPS-induced tau hyperphosphorylation. a The Saa3 gene knockout construct based on information
provided by www.komp.org. Gray boxes are exons, and the hatched area denotes expression-selection cassette. b, c Absence of LPS-induced
expression of the Saa3 transcript (b) and protein (c), in the Saa3−/− mice. The brain tissue from the hippocampi of WT and Saa3−/− mice was
collected 24 h after receiving LPS (15 mg/kg) or saline (control). Tissue homogenate was made for real-time PCR (b) and Western blotting (c).
Representative blots were probed with an anti-Saa3 antibody. β-actin was used as a loading control.***p < 0.01 compared with mice receiving
normal saline (n = 4). d Immunoblots of protein extracts from the hippocampi of WT and Saa3−/− mice receiving LPS (15 mg/kg, 24 h) or saline
(control). Representative blots were probed with anti-phospho-tau antibodies recognizing phosphorylated tau at Thr205 and Ser396 and with
antibodies against non-phosphorylated tau (Tau1) and total tau (Tau5), respectively. β-actin was used as a loading control. e Quantification of the
immunoblots. The relative phosphorylation level of tau in each sample was normalized against the integrated density of total tau (Tau5) present
in each sample. All data shown are mean ± SEM, with four mice in each group; *p < 0.05 compared with WT controls; #p < 0.05 compared with
WT receiving LPS stimulation
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determine whether this effect is unique to Saa3 or gener-
ally applicable to other acute-phase SAA proteins, mice
were given hippocampal injection of recombinant SAA
or saline. The level of total tau and phosphorylated tau
at T205 and S396 was determined in the hippocampus
of mice receiving SAA or saline injection. As shown in
Fig. 4, when normalized against total tau, a decrease in
tau phosphorylation at T205 and S396 was observed in
mice receiving SAA injection compared with mice
receiving saline.
SAA induces microglia activation in mice receiving
intracerebral injection of SAA
It was shown in Fig. 2 that Saa3 was found primarily in
neurons, whereas its expression was absent from micro-
glia. This finding was confirmed in primary cultures of
brain cells. At the mRNA level, marked induction of the
Saa3 transcript was observed in mouse neurons and
astrocytes, but not in microglia (Fig. 5a). Experiments
were conducted to determine whether microglia could
respond to SAA and play a role in neuroinflammation,
as suggested previously [6]. As shown in Fig. 5b and
quantified in Fig. 5c, microglia was markedly activated
in the hippocampus of mice receiving intracerebral
injection of SAA, compared with mice receiving saline
only. This result is consistent with our previous report
that SAA could induce the activation of microglia in
primary culture [6], suggesting a potential role for SAA
in microglial activation.
IL-10 released by SAA-stimulated microglia reduces tau
phosphorylation in primary cultures of neurons
Experiments were conducted to determine whether
SAA acts directly on neurons to affect tau phosphoryl-
ation. As shown in Fig. 6a, SAA treatment of primary
neurons in culture did not have a significant effect on
tau phosphorylation, suggesting that SAA might influ-
ence tau phosphorylation through an indirect mechan-
ism. Since SAA is known to regulate microglial
activation, it was postulated that SAA-treated microglia
might release mediator(s) that affect tau hyperpho-
sphorylation. To test this possibility, primary neurons
from the mice were cultured with conditioned media
(CM) of microglia or astrocyte collected after exposure
to SAA (Fig. 6b). As expected, these cells showed
reduced tau phosphorylation in the presence of the CM
from SAA-treated microglia (Fig. 6c). In comparison,
the level of tau phosphorylation was not changed when
neurons were cultured with CM from SAA-treated
astrocyte (Fig. 6d). This finding confirms our hypoth-
esis that SAA-stimulated microglia release mediator(s)
that affects tau phosphorylation.
We found that the level of IL-10 mRNA was lower in
Saa3−/−mice than in their WT littermate controls fol-
lowing LPS stimulation (Fig. 7a). Consistent with this
finding, the mRNA level of IL-10 was increased after
intracerebral injection of SAA (Fig. 7b). There was also a
remarkable increase in IL-10 protein production in
microglial CM after SAA stimulation (Fig. 7c). To
confirm that IL-10 was the mediator of interest, an anti–
IL-10 monoclonal antibody was included in the culture.
Notably, the effect of microglial CM on tau phosphoryl-
ation was partially reversed with the anti–IL-10 antibody
(Fig. 7d), suggesting involvement of IL-10 in the regula-
tion of tau phosphorylation.
To further explore the potential involvement of IL-10
in the SAA-induced reduction of tau hyperphosphoryla-
tion, mice were given hippocampal injection of recom-
binant SAA with or without the IL-10 neutralizing
antibody. The control mice received hippocampal injec-
tion of saline. The level of total tau and phosphorylated
tau at T205 and S396 was determined. As shown in
Fig. 8, when normalized against total tau, a decrease in
tau phosphorylation at T205 and S396 was observed in
mice receiving intracerebral SAA injection compared
with mice receiving saline. The inclusion of the IL-10
neutralizaing antibody with SAA injection reversed the
decrease in tau phosphorylation at T205 and S396.
Discussion
The present study brings two new findings. One is a
suppressive function of brain SAA in tau hyperpho-
sphorylation, and the other is the involvement of micro-
glia in this function. The majority of the published
studies show that intracellular neurofibrillary tangles
(NFTs) often accompany microglia activation [29], sug-
gesting a possible link between activated microglia and
tau phosphorylation. However, except studies showing
that altered microglia activation play a role in modulat-




































Fig. 4 Intracerebral SAA injection attenuates tau
hyperphosphorylation in mouse brain. a The tau phosphorylation
level from hippocampal extracts was determined by immunoblot
analysis with anti-phospho-tau antibodies at Thr205 and Ser396
following stereotaxical injection of SAA or saline (control) into the
mouse brain. Total tau level and β-actin was also examined. b The
relative tau phosphorylation level for each sample was normalized
the integrated density of total (Tau5) between samples. All data
shown are mean ± SEM; n = 4 mice in each group; *p < 0.05 versus
control group
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CX3CL1-CX3CR1 interaction [30, 31], there has been
no direct evidence for an effect of microglia activation in
tau hyperphosphorylation. Our previous study found
that SAA induces changes in the morphology, survival,
and cytokine production in murine microglia, indicating
that it plays a role in the activation of microglia [6]. The
present study demonstrated for the first time that SAA
is involved in the regulation of microglia activation and
in modulating tau phosphorylation using different
mouse models. Our experimental data confirmed that
IL-10 released from the SAA-stimulated microglia could
affect tau hyperphosphorylation in cultured primary
neurons. Collectively, these results provide new evidence
for an indirect mechanism by which SAA modulates
AD-related pathologies.
In the present study, we evaluated the effect of SAA
on tau hyperphosphorylation using the mouse model of
systemic LPS administration. LPS has been widely uti-
lized in mouse models to induce neuroinflammation via
either systemic administration or direct injection into
the brain [30, 32–35]. Notably, several recent studies
showed that the acute effect of LPS can induce tau
hyperphosphorylation in the mouse brain and worsen
the tau pathology in Tau-Tg mice or 3xTg mice [30, 32,
36–39]. Consistent with these published studies, we




































































Fig. 5 Microglia activation after intracerebral injection of SAA. a LPS-induced Saa3 expression in primary cultures of neurons and astrocytes but
not microglia. Quantitative real-time PCR detection of Saa3 transcript using primary cultures of neurons, microglia, and astrocytes after LPS
stimulation (5, 10, 100, and 1000 ng/ml) for 24 h. Shown are relative mRNA expression levels based on three independent experiments;
mean ± SEM; *p < 0.05 versus controls). b Iba1 stain of the dentate gyrus and CA3 regions of the mouse brain, showing increased microglia
activation, based on Iba 1 expression, in mice receiving brain injection of 20 μg SAA compared to those receiving normal saline. c Quantification
of Iba1 density, based on images in b and similar samples, was expressed as means ± SEM (three sections per animal; three images at dentate
gyrus and CA3 per animal; n = 4 per group; *p < 0.05 compared with the controls (normal saline). Scale bar, 75 μm
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sufficient to induce neuroinflammation and tau hyperpho-
sphorylation. Furthermore, using Saa3−/− mice, our stud-
ies demonstrate that the LPS-induced changes in tau
phosphorylation are altered in Saa3-deficient mice. These
findings provide first evidence for a potential role of the
SAA proteins in LPS-induced tau hyperphosphorylation.
The present study also provides the first documenta-
tion of local expression and distribution of SAA isoforms
in the mouse brain. We found that Saa3 is the predom-
inant SAA isoform induced by systemic LPS administra-
tion in the mouse brain. As a result of this finding, Saa3
was chosen for further analysis using a gene knockout
approach. Because Saa3 is less well characterized for its
regulatory functions compared to the acute-phase SAA
of human origin (SAA1 and SAA2), we have included in
our study a human SAA protein in intracerebral injec-
tion and in the stimulation of cultured brain cells. Both
experiments have given results that complement each
other and together support a regulatory role of SAA in
tau phosphorylation. We have also found that a signifi-
cant amount of the induced Saa3 protein is in neurons
and, to a much lesser extent, astrocytes in the DG region
of hippocampus and in the cortex. However, SAA expres-
sion is negligible in microglia under the same experimen-
tal conditions. This finding is unexpected as previously
published studies have shown that macrophages, which
share many properties with microglia, are a source of SAA
proteins [40]. The discrepancy may result from the effi-
ciency of Saa3 translation in different types of cells and
from the difference in the in vivo (brain sections) and in
vitro (cultured cells) experimental conditions.
Despite the lack of SAA production by microglia, these
cells can nevertheless respond to SAA stimulation with
the release of factors that regulate tau hyperphosphoryla-














































































Fresh medium Conditioned medium(CM)
NeuronsMicroglia/Astrocyte
E
Fig. 6 Soluble factors in SAA-stimulated microglia culture medium
are responsible for the reduced tau phosphorylation in neurons. a
Absence of a direct effect of SAA in tau phosphorylation in neurons.
Primary cultures of mouse neurons were stimulated with 0.5 μM of
SAA for 3, 6, and 12 h. The cells were collected, and tau phosphorylation
was determined with Western blotting using specific antibodies
recognizing phosphorylated tau at T205 and S396. β-actin was a
loading control. b Experimental scheme showing stimulation of
primary astrocytes and microglia with SAA (0.5 μM) or PBS for 6 h,
removal of medium, addition of fresh medium and culture for 12 h,
and collection of conditioned medium (CM) for stimulation of primary
cultures of neurons. c Western blots showing the level of tau
phosphorylation at T205 and S396 after stimulation with 50 % of
CM from cultured astrocytes, as in b. d Western blots showing
the level of tau phosphorylation at T205 and S396 after stimulation
with CM from cultured microglia. The levels of tau phosphorylation at
T205 and S396, as in d and similar samples receiving CM from cultured
microglia, were quantified using densitometry, normalized against
β-actin, and shown in bar graphs in (e; mean ± SEM shown, *p < 0.05;
n = 3 independent cultures)
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SAA directly in assays for tau phosphorylation, suggesting
that the neuron-derived SAA acts through a paracrine
mechanism that involves a mediator. IL-10 is an anti-
inflammatory cytokine known for its inhibition of Aβ- and
LPS-induced pro-inflammatory cytokines and chemokines
in the brain [41]. Two studies have shown that down-
regulation of tau phosphorylation is accompanied by up-
regulation of IL-10 [42, 43], suggesting a possible link
between IL-10 and tau phosphorylation. In the present
study, we demonstrated that IL-10 released by SAA-
stimulated microglia attenuates tau phosphorylation in
neurons, and neutralizing IL-10 could reverse the decrease
of tau phosphorylation induced by intracerebral SAA
injection in mice. These results provide additional evi-
dence for an effect of IL-10 on tau phosphorylation.
Therefore, IL-10 serves to mediate the function of SAA,
which acts indirectly. A previous example of the indirect
action is reported by Harrison et al., who document that
CX3CL1 is produced by neurons in the brain and signals
through CX3CR1, which is expressed in microglia [44, 45].
More interestingly, Kevin Nash et al. found that overex-
pression CX3CL1 in the rTg4510 mouse model directly
suppresses tauopathies [46]. Together, these results provide
evidence for the indirect regulatory mechanism of micro-
glial cells in modulating tau phosphorylation and indicate
that glial cell regulation may be a potential therapeutic
strategy for tauopathies.
Previous study from our laboratory demonstrated that
SAA administration could induce significant activation
of primary microglial cells in culture [6]. Consistent with
this finding, in the present study, stereotaxic hippocam-

















































































































Fig. 7 IL-10 is required for SAA-induced reduction of tau
phosphorylation. a Quantification of real-time PCR for IL-10
transcripts from the hippocampi of WT and Saa3−/− mice receiving LPS
(15 mg/kg, 24 h) or saline (control). Plotted is the relative mRNA
expression calculated as 2-ΔΔCT method and normalized to controls. b
The transcript of IL-10 detected by real-time PCR in brain extracts of
hippocampus 48 h after hippocampal injection of mice with SAA
(20 μg in 8 μl) or equal volume of normal saline. c The level of
IL-10 protein in the CM of primary microglia receiving SAA
(0.5 μM) or PBS, using the stimulation scheme described in Fig. 6b. d
Effect of neutralizing antibody for IL-10 on tau phosphorylation at T205
and S396 after incubation with CM from SAA-stimulated primary
microglia (CM-S). Primary cultures of neurons were stimulated with
50 % CM-S (+) or control (without SAA stimulation, CM-C) for 12 h. The
IL-10 neutralizing antibody (25 μg/ml) was added to CM-S
30 min before application to primary cultures of neurons. The
level of tau phosphorylation at T205 and S396 was determined
by Western blotting using specific anti-phospho-tau antibodies. β-actin
was a loading control. e Quantification of the levels of tau
phosphorylation was conducted using densitometry. The results are
shown in bar graph as mean ± SEM, based on three independent
experiments. *p< 0.05 compared with CM-C stimulated samples;
#p< 0.05 compared with CM-S stimulated samples without
neutralizing antibody
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mouse brain. These findings suggest that the regula-
tory function of SAA may depend on the activation
states of microglia. Both the present study and our
previous study [6] show that SAA can induce the
release of pro-inflammatory cytokines including IL-1β,
IL-6, and TNF-α, as well as the anti-inflammatory
cytokine IL-10. The pro-inflammatory cytokines and anti-
inflammatory cytokines released from SAA-stimulated
microglia may contribute to the homeostatic function of
SAA in the brain. It is through the action of the anti-
inflammatory cytokine IL-10 that SAA exerts its regula-
tory effect on tau phosphorylation. Future studies will be
required to illuminate whether and how other cytokines
released by activated microglia also contribute to the regu-
lation of tau phosphorylation and how SAA-mediated
activation of microglia plays a role in this process.
Conclusions
The present study demonstrates that SAA plays a role in
regulating tau hyperphosphorylation in mice. In these
models, SAA attenuates tau hyperphosphorylation induced
by systemic LPS administration, as evidenced by elevated
tau phosphorylation in Saa3 deficient mice. This effect of
SAA is not exerted directly on neurons; instead, IL-10
released by the SAA-activated microglia serves to inhibit
tau hyperphosphorylation. Our results suggest that SAA is
a potential target for therapeutic intervention of AD.
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